What is Haisco Pharmaceutical Group Co., Ltd.'s (002653.SZ) StockRank?

MoatMap's StockRank for Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) is 56/100, with a Hold signal. This is a composite score combining Quality (70), Value (13), and Momentum (62) factor ranks across MoatMap's 20,000+ stock universe.

Does Haisco Pharmaceutical Group Co., Ltd. have an economic moat?

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) has a Quality factor score of 70/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Haisco Pharmaceutical Group Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) is Hold, based on a StockRank of 56/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Haisco Pharmaceutical Group Co., Ltd. in?

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) operates in the Healthcare sector, specifically the Biotechnology industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

002653.SZ

HOLDREMOVE

Haisco Pharmaceutical Group Co., Ltd. · Healthcare · China · $8.5B · Avg Vol: $33M/d

StockRank

P/E (TTM)

70.8x

ROE

17.1%

D/E

0.5x

Dividend %

0.5%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Haisco Pharmaceutical has high quality scores but operates primarily in the domestic Chinese generic and innovative drug market, which is subject to severe regulatory price-cutting (VBP) and lacks global thematic tailwinds.

COMPANY DESCRIPTION

Haisco Pharmaceutical Group is a leading Chinese pharmaceutical company specializing in clinical nutrition, anesthetics, and innovative small-molecule drugs. The company holds a dominant market position in China's parenteral nutrition and specialized perioperative drug segments. Its growth is increasingly driven by a robust pipeline of proprietary, first-in-class and best-in-class clinical candidates.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	446M	496M	550M	648M	13.3%
EPS	0.04	0.04	0.05	0.03	-4.0%
Shares	1.1B	1.1B	1.1B	1.1B	+4.1%
Debt	311M	267M	282M	293M	-2.0%
Equity	449M	618M	623M	634M	12.2%
Op CF	14M	66M	65M	116M	102.6%
Inv CF	-80M	-57M	-45M	-23M	—
Fin CF	92M	48M	-37M	-43M	—

PRICE (1M)-9.5%

SMA 50SMA 200

$7.28

RSI (14)

41.4

52W High

$9.21

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

5.6%58.8

ROE

17.1%85.7

GP/Assets

54.0%88.6

Op. Margin

36.2%95.5

FCF/Assets

9.0%84.2

Piotroski

—83.4

Int. Cover

9.4x63.5

D/E Ratio

0.46x33.6

Current Ratio

2.02x37.3

Value

P/E (TTM)

70.8x13.7

EV/EBITDA

58.7x5.6

P/FCF

624.5x12.6

P/B

11.2x9.2

P/S

10.8x24.7

Div Yield

0.5%15.6

Momentum

52W High %

79%71.9

RS 6M

-29%44.5

SMA 50/200

1.00x63.2

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+39%48.7

Q Growth

1090%97.5

FUNDAMENTALS

Market Cap

$8.5B

P/E (Forward)

50.9x

Gross Margin

74.5%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 002653.SZ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
002653.SZ	Haisco Pharmaceutical Group Co., Ltd.(you)	$8.5B	56	HOLD
688331.SS	RemeGen Co., Ltd.	$9.7B	48	HOLD
6990.HK	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	$13.7B	60	HOLD
300759.SZ	Pharmaron Beijing Co., Ltd.	$6.8B	44	HOLD
688278.SS	Xiamen Amoytop Biotech Co., Ltd.	$3.4B	57	HOLD
1801.HK	Innovent Biologics, Inc.	$18.5B	49	HOLD
688428.SS	InnoCare Pharma Limited	$6.4B	40	HOLD
2696.HK	Shanghai Henlius Biotech, Inc.	$4.8B	45	HOLD
600161.SS	Beijing Tiantan Biological Products Co., Ltd.	$4.0B	46	HOLD
2315.HK	Biocytogen Pharmaceuticals (Beijing) Co., Ltd.	$2.8B	60	HOLD

Peer medians: ROE 4.7% · P/E 27.6x · Gross margin 53.0%

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) — Stock Score Summary

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) has a MoatMap StockRank of 56/100 based on Quality (70/100), Value (13/100), and Momentum (62/100) factor scores. The current signal is HOLD. Haisco Pharmaceutical has high quality scores but operates primarily in the domestic Chinese generic and innovative drug market, which is subject to severe regulatory price-cutting (VBP) and lacks global thematic tailwinds.

Key Financial Metrics

Price	$7.28
Market Cap	$8.5B
P/E (TTM)	70.83
P/E (Forward)	50.91
Price/Book	11.19
Return on Equity	17.1%
Return on Invested Capital	5.6%
Debt/Equity	46.19
Gross Margin	74.5%
Operating Margin	36.2%
Revenue Growth	75.3%
Dividend Yield	0.5%
Free Cash Flow	$14M

Haisco Pharmaceutical Group Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Haisco Pharmaceutical Group Co., Ltd.’s (002653.SZ) StockRank?: MoatMap’s StockRank for Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) is 56/100, with a Hold signal. It is a composite of Quality (70), Value (13), and Momentum (62) factor ranks across MoatMap’s 20,000+ stock universe.
Does Haisco Pharmaceutical Group Co., Ltd. have an economic moat?: Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) has a Quality factor score of 70/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Haisco Pharmaceutical Group Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) is Hold, based on a StockRank of 56/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Haisco Pharmaceutical Group Co., Ltd. in?: Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) operates in the Healthcare sector, specifically the Biotechnology industry (China).